# OnCo record nodular-lymphocyte-predominant-hodgkin-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "nodular-lymphocyte-predominant-hodgkin-lymphoma" ;
  schema:name "Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)"@en ;
  schema:alternateName "NLPHL"@en, "NLPBL"@en, "Nodular lymphocyte-predominant B-cell lymphoma"@en, "Lymphocyte-predominant Hodgkin disease"@en, "Popcorn cell lymphoma"@en ;
  schema:description "Nodular lymphocyte-predominant Hodgkin lymphoma is the rare, slow-growing cousin of classical Hodgkin lymphoma, so different in its CD20-bearing cells that the WHO renamed it a B-cell lymphoma in 2022. Early disease is usually cured with radiotherapy alone or surgery in children, advanced disease with rituximab-based chemotherapy, and patients are followed for life because it can return late."@en ;
  schema:url <https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Nodular_lymphocyte_predominant_Hodgkin_lymphoma> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439>, <https://en.wikipedia.org/wiki/Nodular_lymphocyte_predominant_Hodgkin_lymphoma> ;
  onco:tag "subtype-page", "haematologic" ;
  onco:related <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/active-surveillance/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/> ;
  onco:terms <https://onco.cc/terms/r-chop/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/terms/lymphoma-type/>, <https://onco.cc/terms/lugano-classification/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-who-2022-lymphoid-alaggio-leukemia-2022/>, <https://onco.cc/key-papers/paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020/> ;
  onco:pipeline <https://onco.cc/drugs/rituximab/> ;
  onco:standardOfCare <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/lymphoma-type/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/drugs/rituximab/> .